Disparities in adoption of new diabetic therapies with cardiovascular benefits
Authors' conclusion
Prescriptionof SGLT2i or GLP1a was lower among patients with cardiovascular co-morbidities and those who identified as Black, Hispanic or Asian. Further efforts to minimize these disparities should be pursued.
Study context
- Population
- Patients with clinic visit between January 1, 2018 and January 1, 2019, de-identified claims data
- Exposure
- SGLT2i or GLP-1 RA use across socioeconomic strata, medical risk and provider type
- Outcome
- Composite of:
- A medication fill of either an SGLT2i
- GLP1a
- Follow-up
- Within 180 days of the index visit
Methodological detailsde-identified claims data
- De-identified claims data
Main finding
As reported in the abstract
Fill of SGLT2i and/or GLP1a · within 180 days of index visit
- Black · lower odds
- aOR 0.81; P < 0.000
- Hispanic · lower odds
- aOR 0.87; P < 0.000
- Asian · lower odds
- aOR 0.83; P < 0.000
- Endocrinologist vs Primary care clinician · higher odds
- aOR 2.12; P < 0.000
- Heart failure
- odds 0.64; P = 0.006
- Received either a GLP-1a or SGLT2i
- 125,636 (15.8 %)
Observational data: associations, not effects.
Original publication
Disparities in adoption of new diabetic therapies with cardiovascular benefits. Diabetes Res Clin Pract. Published 26 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →